Ulf Jungnelius, MD

Education/Background:  Oncology Specialist with a diploma from Karolinska Institute, along with clinical experience from Radiumhemmet in Stockholm. Dr. Jungnelius has extensive experience in international clinical research & development in the field of oncology. He has held executive positions at several international companies such as Eli Lilly, Pfizer, Takeda, and Celgene.

Current Assignments: CEO at HealthCom GmbH (CH), CMO at TME Pharma, Board Positions: Oncopeptides AB, Beactica AB and Ryvu Therapeutics.

Stock options: 25,000 TO10